A detailed characterisation of drug resistance during darunavir/ritonavir (DRV/r) monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance
Abstract Background Maintenance monotherapy with DRV/r has yielded variable outcomes and is not recommended. Trial samples offer valuable opportunities for detailed studies. We analysed samples from a 48-week trial in Cameroon to obtain a detailed characterisation of drug resistance.Methods Following failure of NNRTI-based therapy and virological suppression on PI-based therapy, participants were assigned to receive either DRV/r (n=81) or TDF/3TC + LPV/r (n=39). PBMC from study entry underwent bulk protease and RT sequencing. Plasma collected at virological rebound (confirmed or last available HIV-1 RNA >60 copies/ml) underwent ultradeep protease and RT sequencing and bulk gag-protease sequencing. A site-directed mutant with T375A (p2/p7) was phenotypically characterised using a single-cycle assay.Results HIV-1 DNA analysis revealed NRTI and NNRTI resistance-associated mutations (RAMs) in 52/90 (57.8%) and 53/90 (58.9%) samples, respectively. In rebound HIV-1 RNA (DRV/r n=21; LPV/r n=2), prevalence was 9/23 (39.1%) and 10/23 (43.5%), respectively, with most RAMs occurring at frequencies ≥15%. No DRV RAMs were found. Paired HIV-1 DNA and RNA sequences showed partial consistency in resistance patterns. Among 8 participants experiencing virological rebound on DRV/r (n=12 samples), all showed gag mutations associated with PI-exposure, including T375N, T375A (p2/p7), K436R (p7/p1), and mutations in p17, p24, p2 and p6. T375A conferred 10-fold DRV resistance and increased replication capacity.Conclusions The study highlights the high resistance barrier of DRV/r while identifying alternative pathways of DRV resistance through gag substitutions. During virological suppression, resistance patterns in HIV-1 DNA reflect treatment history, but due to technical and biological considerations, cautious interpretation is warranted..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 19. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdullahi, Adam [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.10.15.562382 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI041191781 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI041191781 | ||
| 003 | DE-627 | ||
| 005 | 20231205143935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231016s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.10.15.562382 |2 doi | |
| 035 | |a (DE-627)XBI041191781 | ||
| 035 | |a (biorXiv)10.1101/2023.10.15.562382 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdullahi, Adam |e verfasserin |0 (orcid)0000-0001-9703-8264 |4 aut | |
| 245 | 1 | 0 | |a A detailed characterisation of drug resistance during darunavir/ritonavir (DRV/r) monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Maintenance monotherapy with DRV/r has yielded variable outcomes and is not recommended. Trial samples offer valuable opportunities for detailed studies. We analysed samples from a 48-week trial in Cameroon to obtain a detailed characterisation of drug resistance.Methods Following failure of NNRTI-based therapy and virological suppression on PI-based therapy, participants were assigned to receive either DRV/r (n=81) or TDF/3TC + LPV/r (n=39). PBMC from study entry underwent bulk protease and RT sequencing. Plasma collected at virological rebound (confirmed or last available HIV-1 RNA >60 copies/ml) underwent ultradeep protease and RT sequencing and bulk gag-protease sequencing. A site-directed mutant with T375A (p2/p7) was phenotypically characterised using a single-cycle assay.Results HIV-1 DNA analysis revealed NRTI and NNRTI resistance-associated mutations (RAMs) in 52/90 (57.8%) and 53/90 (58.9%) samples, respectively. In rebound HIV-1 RNA (DRV/r n=21; LPV/r n=2), prevalence was 9/23 (39.1%) and 10/23 (43.5%), respectively, with most RAMs occurring at frequencies ≥15%. No DRV RAMs were found. Paired HIV-1 DNA and RNA sequences showed partial consistency in resistance patterns. Among 8 participants experiencing virological rebound on DRV/r (n=12 samples), all showed gag mutations associated with PI-exposure, including T375N, T375A (p2/p7), K436R (p7/p1), and mutations in p17, p24, p2 and p6. T375A conferred 10-fold DRV resistance and increased replication capacity.Conclusions The study highlights the high resistance barrier of DRV/r while identifying alternative pathways of DRV resistance through gag substitutions. During virological suppression, resistance patterns in HIV-1 DNA reflect treatment history, but due to technical and biological considerations, cautious interpretation is warranted. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Diaz, Ana Garcia |4 aut | |
| 700 | 1 | |a Fopoussi, Olga Mafotsing |4 aut | |
| 700 | 1 | |a Beloukas, Apostolos |4 aut | |
| 700 | 1 | |a Defo, Victoire Fokom |4 aut | |
| 700 | 1 | |a Kouanfack, Charles |4 aut | |
| 700 | 1 | |a Torimiro, Judith |4 aut | |
| 700 | 1 | |a Geretti, Anna Maria |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 19. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.10.15.562382 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 19 |c 10 | ||